Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian A Rowe

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
The New England Journal of Medicine|September 17, 2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitisMatthew J Armstrong, Diarmaid D Houlihan, Ian A Rowe
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 12, 2021
Treatment Candidacy for Pharmacologic Therapies for NASHIan A Rowe, Vincent Wai-Sun Wong, Rohit Loomba
Gastroenterology|August 8, 2017
Transplant-Free Survival Rates After Covered Transjugular Intrahepatic Portosystemic ShuntDaniel Schmidt-Martin, Matthew J Armstrong, Ian A Rowe
Journal of Hepatology|June 3, 2026
Agree to disagree; increasing the impact of recommendations formulated through Delphi methodologyOliver D Tavabie, Paul N Brennan, Ian A Rowe
Hepatology (Baltimore, Md.)|January 4, 2012
Prioritizing treatment experienced patients with hepatitis C infection for treatment with telaprevir: a number needed to treat approachIan A Rowe, Matthew J Armstrong, Diarmaid D Houlihan
Journal of Hepatology|September 13, 2018
Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver diseaseJessica Shearer, David Chizhande, Rebecca Jones, et al.
BMJ (Clinical Research Ed.)|July 14, 2017
Should we screen for cirrhosis?Mark Hudson, Nick Sheron, Ian A Rowe, et al.
Hepatology (Baltimore, Md.)|January 21, 2012
Informed consent in surveillance for hepatocellular carcinoma in patients with cirrhosisIan A Rowe, Matthew J Armstrong, Richard Parker, et al.
Hepatology (Baltimore, Md.)|June 13, 2017
Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choicesEleanor J Taylor, Rebecca L Jones, J Ashley Guthrie, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 26, 2022
The Natural History of Advanced Chronic Liver Disease Defined by Transient ElastographyJessica E Shearer, Rebecca Jones, Richard Parker, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
The New England Journal of Medicine|September 17, 2010
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitisMatthew J Armstrong, Diarmaid D Houlihan, Ian A Rowe
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 12, 2021
Treatment Candidacy for Pharmacologic Therapies for NASHIan A Rowe, Vincent Wai-Sun Wong, Rohit Loomba
Gastroenterology|August 8, 2017
Transplant-Free Survival Rates After Covered Transjugular Intrahepatic Portosystemic ShuntDaniel Schmidt-Martin, Matthew J Armstrong, Ian A Rowe
Journal of Hepatology|June 3, 2026
Agree to disagree; increasing the impact of recommendations formulated through Delphi methodologyOliver D Tavabie, Paul N Brennan, Ian A Rowe
Hepatology (Baltimore, Md.)|January 4, 2012
Prioritizing treatment experienced patients with hepatitis C infection for treatment with telaprevir: a number needed to treat approachIan A Rowe, Matthew J Armstrong, Diarmaid D Houlihan
Journal of Hepatology|September 13, 2018
Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver diseaseJessica Shearer, David Chizhande, Rebecca Jones, et al.
BMJ (Clinical Research Ed.)|July 14, 2017
Should we screen for cirrhosis?Mark Hudson, Nick Sheron, Ian A Rowe, et al.
Hepatology (Baltimore, Md.)|January 21, 2012
Informed consent in surveillance for hepatocellular carcinoma in patients with cirrhosisIan A Rowe, Matthew J Armstrong, Richard Parker, et al.
Hepatology (Baltimore, Md.)|June 13, 2017
Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choicesEleanor J Taylor, Rebecca L Jones, J Ashley Guthrie, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 26, 2022
The Natural History of Advanced Chronic Liver Disease Defined by Transient ElastographyJessica E Shearer, Rebecca Jones, Richard Parker, et al.
Pageof 10